miR-125a-5p在非小细胞肺癌血清中的表达及其意义
|
摘要
目的探究miR-125a-5p在非小细胞肺癌(NSCLC)患者血清中的表达情况,分析miR-125a-5p与临床病理特征之间的相关性及其在NSCLC早期诊断中的意义。方法收集2017年7月至2018年3月安徽医科大学附属巢湖医院44例NSCLC患者为试验组和20例体检的健康志愿者为对照组。采用Q-PCR术检测NSCLC患者和健康者外周血清miR-125a-5p的表达量,并评估其临床意义。结果试验组血清miR-125a-5p相对表达量为0. 025(0. 017,0. 051),低于对照组的0. 050(0. 034,0. 117),差异有统计学意义(P <0. 05)。试验组患者miR-125a-5p的表达量与临床TNM分期呈负相关性(r=-0. 688,P <0. 05),而在性别、年龄、吸烟、组织分型间差异无统计学意义,与癌胚抗原(CEA)、细胞角蛋白19片段抗原(CYFRA21-1)水平均无相关性(P> 0. 05)。试验组患者CEA、CYFRA21-1的表达量与临床TNM分期均无相关性(P> 0. 05)。结论 miR-125a-5p在NSCLC患者血清中表达下调,对NSCLC早期诊断优于CEA、CYFRA21-1,可能成为NSCLC早期诊断的重要生物学指标。
Objective To investigate the expression of miR-125a-5p in serum of patients with non-small cell lung cancer( NSCLC),and to analyze the correlation between miR-125a-5p and clinicopathological characteristics and its significance in early diagnosisof NSCLC. Methods 44 NSCLC patients in Chaohu Hospital of Anhui Medical University were selected as experimental group and 20 healthy volunteers as control group from July 2017 to March 2018. The expression levels of miR-125a-5p in peripheral blood of the subjects were detected by Q-PCR,and its clinical significance was evaluated. Results The relative expression level of miR-125a-5p in serum of experimental group was 0. 025( 0. 017,0. 051),which was lower than that in control group 0. 050( 0. 034,0. 117),and the difference was statistically significant( P < 0. 05). The expression of miR-125a-5p in experimental group was negatively correlated with clinical TNM stage( r =-0. 688,P < 0. 05),but not correlated with CEA and cyfra21-1 levels( P > 0. 05). There was no statistically significant difference in the expression of miR-125a-5p in sex,age,smoking and tissue typing in experimental group. Conclusion MiR-125a-5p is down-regulated in serum of NSCLC patients,which is better than CEA and cyfra21-1 in early diagnosis of NSCLC,and may be an important biological marker for early diagnosis of NSCLC.
Objective To investigate the expression of miR-125a-5p in serum of patients with non-small cell lung cancer( NSCLC),and to analyze the correlation between miR-125a-5p and clinicopathological characteristics and its significance in early diagnosisof NSCLC. Methods 44 NSCLC patients in Chaohu Hospital of Anhui Medical University were selected as experimental group and 20 healthy volunteers as control group from July 2017 to March 2018. The expression levels of miR-125a-5p in peripheral blood of the subjects were detected by Q-PCR,and its clinical significance was evaluated. Results The relative expression level of miR-125a-5p in serum of experimental group was 0. 025( 0. 017,0. 051),which was lower than that in control group 0. 050( 0. 034,0. 117),and the difference was statistically significant( P < 0. 05). The expression of miR-125a-5p in experimental group was negatively correlated with clinical TNM stage( r =-0. 688,P < 0. 05),but not correlated with CEA and cyfra21-1 levels( P > 0. 05). There was no statistically significant difference in the expression of miR-125a-5p in sex,age,smoking and tissue typing in experimental group. Conclusion MiR-125a-5p is down-regulated in serum of NSCLC patients,which is better than CEA and cyfra21-1 in early diagnosis of NSCLC,and may be an important biological marker for early diagnosis of NSCLC.
引文
[1]FENG B,ZHANG K,WANG R,et al.Non-small-cell lung cancer and miRNAs:novel biomarkers and promising tools for treatment[J].Clin Sci(Lond),2015,129(7):673.
[2]OTT C L,RATNA N,PRAYAG R,et al.Survival and treatment patterns in elderly patients with advanced non-smallcell lung cancer in Manitoba[J].Curr Oncol,2011,18(5):e238-e242.
[3]MO D,GU B,GONG X,et al.miR-1290 is a potential prognostic biomarker in non-small cell lung cancer[J].JThorac Dis,2015,7(9):1570-1579.
[4]RUSEK A M,ABBA M,ELJASZEWICZ A,et al.MicroR-NA modulators of epigenetic regulation,the tumor microenvironment and the immune system in lung cancer[J].Mol Cancer,2015,14(1):34.
[5]MITCHELL P S,PARKIN R K,KROH E M,et al.Circulating microRNAs as stable blood-based markers for cancer detection[J].Proc Natl Acad Sci USA,2008,105(30):10513-10518.
[6]叶波,赵珩.第八版国际肺癌TNM分期修订稿解读[J].中国肺癌杂志,2016,19(6):337-342.
[7]BAI J,ZHU X,MA J,et al.miR-205 regulates A549cells proliferation by targeting PTEN[J].Int J Clin Exp Pathol,2015,8(2):1175-1183.
[8]POPPER H H,RYSKA A,TIMIR J,et al.Molecular testing in lung cancer in the era of precision medicine[J].Transl Lung Cancer Res,2014,3(5):291-300.
[9]JUNG M,KIM S H,LEE Y J,et al.Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib[J].Exp Ther Med,2011,2(4):685-693.
[10]ZHU W Y,LUO B,AN J Y,et al.Differential expression of miR-125a-5p and let-7e predicts the progression and prognosis of non-small cell lung cancer[J].Cancer Invest,2014,32(8):394-401.
[11]HASHIGUCHI Y,NISHIDA N,MIMORI K,et al.Downregulation of miR-125a-3p in human gastric cancer and its clinicopathological,significance[J].Int J Oncol,2012,40(5):1477-1482.
[12]BI Q,TANG S,XIA L,et al.Ectopic Expression of MiR-125a inhibits the proliferation and metastasis of hepatocellular carcinoma by targeting MMP11 and VEGF[J].PLo SOne,2012,7(6):e40169.
[13]于筱舟,魏枫,闫帆,等.非小细胞肺癌组织中低表达microRNA谱[J].中国肿瘤临床,2014,41(5):291-295.
[14]张洪川,徐艳梅,周璞,等.血浆检测microRNA-125a-3p、IGF-2在监测NSCLC侵袭转移中的价值[J].重庆医学,2014,43(14):1700-1702.
[15]侯太辉,邱亚梅,翟宗岗.miR-125a对肺癌细胞增殖、凋亡及侵袭能力的研究[J].中国地方病防治杂志,2016,31(12):1388-1399.
[16]王怡,马虎.miR-125在NSCLC EGFR-TKIs耐药前后血清中的表达及临床意义[D].贵州遵义:遵义医学院,2017.
[2]OTT C L,RATNA N,PRAYAG R,et al.Survival and treatment patterns in elderly patients with advanced non-smallcell lung cancer in Manitoba[J].Curr Oncol,2011,18(5):e238-e242.
[3]MO D,GU B,GONG X,et al.miR-1290 is a potential prognostic biomarker in non-small cell lung cancer[J].JThorac Dis,2015,7(9):1570-1579.
[4]RUSEK A M,ABBA M,ELJASZEWICZ A,et al.MicroR-NA modulators of epigenetic regulation,the tumor microenvironment and the immune system in lung cancer[J].Mol Cancer,2015,14(1):34.
[5]MITCHELL P S,PARKIN R K,KROH E M,et al.Circulating microRNAs as stable blood-based markers for cancer detection[J].Proc Natl Acad Sci USA,2008,105(30):10513-10518.
[6]叶波,赵珩.第八版国际肺癌TNM分期修订稿解读[J].中国肺癌杂志,2016,19(6):337-342.
[7]BAI J,ZHU X,MA J,et al.miR-205 regulates A549cells proliferation by targeting PTEN[J].Int J Clin Exp Pathol,2015,8(2):1175-1183.
[8]POPPER H H,RYSKA A,TIMIR J,et al.Molecular testing in lung cancer in the era of precision medicine[J].Transl Lung Cancer Res,2014,3(5):291-300.
[9]JUNG M,KIM S H,LEE Y J,et al.Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib[J].Exp Ther Med,2011,2(4):685-693.
[10]ZHU W Y,LUO B,AN J Y,et al.Differential expression of miR-125a-5p and let-7e predicts the progression and prognosis of non-small cell lung cancer[J].Cancer Invest,2014,32(8):394-401.
[11]HASHIGUCHI Y,NISHIDA N,MIMORI K,et al.Downregulation of miR-125a-3p in human gastric cancer and its clinicopathological,significance[J].Int J Oncol,2012,40(5):1477-1482.
[12]BI Q,TANG S,XIA L,et al.Ectopic Expression of MiR-125a inhibits the proliferation and metastasis of hepatocellular carcinoma by targeting MMP11 and VEGF[J].PLo SOne,2012,7(6):e40169.
[13]于筱舟,魏枫,闫帆,等.非小细胞肺癌组织中低表达microRNA谱[J].中国肿瘤临床,2014,41(5):291-295.
[14]张洪川,徐艳梅,周璞,等.血浆检测microRNA-125a-3p、IGF-2在监测NSCLC侵袭转移中的价值[J].重庆医学,2014,43(14):1700-1702.
[15]侯太辉,邱亚梅,翟宗岗.miR-125a对肺癌细胞增殖、凋亡及侵袭能力的研究[J].中国地方病防治杂志,2016,31(12):1388-1399.
[16]王怡,马虎.miR-125在NSCLC EGFR-TKIs耐药前后血清中的表达及临床意义[D].贵州遵义:遵义医学院,2017.